Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Meta Expands AI Training With Employee Activity Tracking Tools 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
ATLANTA, Feb. 29, 2016 -- Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 36th Annual Cowen Healthcare Conference, to be held March 7-9, 2016 at the The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Wednesday, March 9, 2016 at 8:00 AM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimerasciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences
Alimera Sciences (NASDAQ:ALIM) (Alimera), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases.
For more information, please visit www.alimerasciences.com.
COCKRELL GROUP 877.889.1972 [email protected] cockrellgroup.com
